Search
Search results
205 results found
Inaugural Merkin Prize in Biomedical Technology Celebrated at the Broad Institute of MIT and Harvard
BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models.
Rauh, Ulrike, Guo Wei, Michael Serrano-Wu, Georgios Kosmidis, Stefan Kaulfuss, Franziska Siegel, Kai Thede, et al. 2024. “BRD-810 Is a Highly Selective MCL1 Inhibitor With Optimized in Vivo Clearance and Robust Efficacy in Solid and Hematological Tumor Models.”. Nat Cancer 5: 1479-93.
Brain-region-specific changes in neurons and glia and dysregulation of dopamine signaling in Grin2a mutant mice
Farsi, Zohreh. 2023. “Brain-Region-Specific Changes in Neurons and Glia and Dysregulation of Dopamine Signaling in Grin2a Mutant Mice”. Neuron.
Dec 2024 A-BIG-NET Newsletter
Welcome All to the Inaugural Issue of A-BIG-NET’s Newsletter! We’re thrilled to bring you the very first edition of our bi-annual scientific newsletter, designed to keep you up-to-date with the latest developments, insights, and achievements across the A-BIG-NET project. Moving forward, you can...
Scalable, compressed phenotypic screening using pooled perturbations
Liu, Nuo, Walaa Kattan, Benjamin Mead, Conner Kummerlowe, Thomas Cheng, Sarah Ingabire, Jamie H. Cheah, et al. 2024. “Scalable, Compressed Phenotypic Screening Using Pooled Perturbations”. Nature Biotechnology.
News Headline 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus...
News Headline 4
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus...
Team
Andrew Navia
Andrew Navia, PhD Andrew is interested in using single-cell techniques to study new RNA states in solid tumors. This builds on work completed during his PhD in the Shalek Lab at MIT. In his free time he enjoys hiking and running.